{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:42:15Z","timestamp":1788399735702,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.chest.2022.08.2233","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:04:08Z","timestamp":1662649448000},"page":"345-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Yet H.","family":"Khor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Hambly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri A.","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene H.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Assayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Manganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2022.08.2233_bib1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur Respir J"},{"issue":"157","key":"10.1016\/j.chest.2022.08.2233_bib2","doi-asserted-by":"crossref","first-page":"190158","DOI":"10.1183\/16000617.0158-2019","article-title":"Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review","volume":"29","author":"Khor","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"11","key":"10.1016\/j.chest.2022.08.2233_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.rmed.2005.03.007","article-title":"Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation","volume":"99","author":"Kawut","year":"2005","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2022.08.2233_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1164\/rccm.200604-520OC","article-title":"Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis","volume":"174","author":"Lederer","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2022.08.2233_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2008.07.022","article-title":"Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis","volume":"103","author":"Caminati","year":"2009","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2022.08.2233_bib6","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1183\/09031936.00131813","article-title":"6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis","volume":"43","author":"du Bois","year":"2014","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2022.08.2233_bib7","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.rmed.2006.02.004","article-title":"The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis","volume":"100","author":"Lettieri","year":"2006","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2022.08.2233_bib8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.08.2233_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3562923","article-title":"The Canadian Registry for Pulmonary Fibrosis: design and rationale of a national pulmonary fibrosis registry","volume":"2016","author":"Ryerson","year":"2016","journal-title":"Can Respir J"},{"issue":"2","key":"10.1016\/j.chest.2022.08.2233_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2022.08.2233_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"ATS\/ERS\/JRS\/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2022.08.2233_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"ATS\/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.08.2233_bib13","doi-asserted-by":"crossref","unstructured":"Hambly N, Farooqi MM, Dvorkin-Gheva A, et\u00a0al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry [published online ahead of print March 10, 2022]. Eur Respir J. doi:10.1183\/13993003.02571-2021","DOI":"10.1183\/13993003.02571-2021"},{"issue":"1","key":"10.1016\/j.chest.2022.08.2233_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2022.08.2233_bib15","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease: an official American Thoracic Society clinical practice guideline","volume":"202","author":"Jacobs","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"446","key":"10.1016\/j.chest.2022.08.2233_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.chest.2022.08.2233_bib17","doi-asserted-by":"crossref","unstructured":"Chandel A, Pastre J, Valery S, King CS, Nathan SD. Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis [published online ahead of print March 24, 2022]. Thorax. doi:10.1136\/thoraxjnl-2021-218440","DOI":"10.1136\/thoraxjnl-2021-218440"},{"issue":"4","key":"10.1016\/j.chest.2022.08.2233_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2022.08.2233_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.09.010","article-title":"Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?","volume":"169","author":"Clarke","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.chest.2022.08.2233_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2022.08.2233_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2022.08.2233_bib22","first-page":"584","article-title":"Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis","volume":"55","author":"Modrykamien","year":"2010","journal-title":"Respir Care"},{"issue":"11","key":"10.1016\/j.chest.2022.08.2233_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.rmed.2012.07.013","article-title":"Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis","volume":"106","author":"Minai","year":"2012","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2022.08.2233_bib24","first-page":"297","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis does not influence six-minute walk distance: results from a retrospective study","volume":"31","author":"Harari","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.chest.2022.08.2233_bib25","first-page":"CD006322","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.chest.2022.08.2233_bib26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2022.08.2233_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2022.08.2233_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.chest.2022.08.2233_bib29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2022.08.2233_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.rmed.2013.04.002","article-title":"Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease","volume":"107","author":"Holland","year":"2013","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2022.08.2233_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1164\/rccm.200604-488OC","article-title":"Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test","volume":"174","author":"Flaherty","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2022.08.2233_bib32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200302-219OC","article-title":"Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia","volume":"168","author":"Lama","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2022.08.2233_bib33","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.chest.2021.04.037","article-title":"Incidence and prognostic significance of hypoxemia in fibrotic interstitial lung disease: an international cohort study","volume":"160","author":"Khor","year":"2021","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2022.08.2233_bib34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4187\/respcare.06615","article-title":"Predictors of impaired survival in subjects with long-term oxygen therapy","volume":"64","author":"Rantala","year":"2019","journal-title":"Respir Care"},{"issue":"7","key":"10.1016\/j.chest.2022.08.2233_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.rmed.2015.04.008","article-title":"Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk\u00a0test in patients with idiopathic pulmonary fibrosis","volume":"109","author":"Nathan","year":"2015","journal-title":"Respir Med"},{"issue":"22","key":"10.1016\/j.chest.2022.08.2233_bib36","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.08.2233_bib37","article-title":"Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)","volume":"6","author":"Maher","year":"2019","journal-title":"BMJ Open Respir Res"},{"issue":"9779","key":"10.1016\/j.chest.2022.08.2233_bib38","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2022.08.2233_bib39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2022.08.2233_bib40","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American Thoracic Society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2022.08.2233_bib41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2022.08.2233_bib42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1378\/chest.09-0211","article-title":"Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis","volume":"136","author":"Swigris","year":"2009","journal-title":"Chest"}],"updated-by":[{"DOI":"10.1016\/j.chest.2024.04.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222037096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222037096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:04:07Z","timestamp":1715130247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222037096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0012369222037096"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.08.2233","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.chest.2024.04.002","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.08.2233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}